Poster Abstracts • OFID 2017:4 (Suppl 1) • S111 an ABSSSI diagnosis presenting to two academic medical centers in Detroit, MI from 2010 to 2015 were included. Baseline/clinical characteristics and outcomes were compared between cases (ABSSSI + BSI) and controls (ABSSSI). Outcomes included in-hospital mortality, hospital length of stay (los) and 30-day reinfection. Fisher's exact and Student's t-or Mann-Whitney U-tests were used for bivariate comparisons. Variables associated with ABSSSI + BSI in bivariate analysis at a P-value < 0.1 were included in multivariable logistic regression to examine factors independently associated with ABSSSI + BSI.
Post-Discharge Antibiotic Therapy in Patients with
Background. There are limited published data regarding the post-discharge treatment epidemiology for most infections, including acute bacterial skin and skin structure infections (ABSSSIs).
Methods. This is a national descriptive study of Veterans Affairs medical center admissions with diagnosis codes for ABSSSIs between January 1, 2005 and September 30, 2015. Patients receiving vancomycin during this admission were selected for inclusion. Treatment approaches after hospital discharge, including oral antibiotics, as well as intravenous (IV) medications administered in an outpatient clinic were assessed. Differences between oral and IV groups were assessed with χ 2 or Wilcoxon tests as appropriate.
Results. Of the 118,135 ABSSSI admissions, 114,352 (96.8%) patients continued antibiotic therapy after discharge. Most patients (98.5%) continued on oral therapy (median length of stay 4 days vs 6 days in IV group; P < 0.05). The most common oral therapies after discharge were sulfamethoxazole/trimethoprim (n = 30,220, 26.8%) and amoxicillin clavulanate (n = 21,819, 19.4%). The most common IV antibiotics were vancomycin (n = 740, 57.5%) and ceftriaxone (n = 220, 17.1%). Significant differences in demographics and comorbidities were observed between the oral and IV groups; however, absolute differences were negligible in some cases (e.g., median age 61 in oral group and 62 in IV group). Cultures were taken in less than half of patients (37.9% oral, 49.7% IV; P < 0.05), of which most were Staphylococcus aureus (81.7% oral, 78.4% IV; P < 0.05), with higher methicillin resistance in the IV group (59.1% oral, 63.7% IV; P < 0.05). In unadjusted comparisons between the oral and IV groups, the following 30-day outcomes differed significantly (P < 0.05): emergency room visit (21.6% oral, 45.3% IV), readmission (13.8% oral, 25.5% IV), and reinfection (45.7% oral, 54.3% IV).
Conclusion. Most patients with ABSSSI admissions continued antibiotic therapy after discharge, with only 1.1% receiving IV antibiotics in an outpatient clinic after discharge. Demographic characteristics and comorbidity burden were similar between the oral and IV groups; however, small absolute differences were statistically significant as this was a large cohort. 
Methods. Retrospective chart review was performed for patients discharged from Abbott Northwestern Hospital (ANW) with primary diagnosis of skin and soft-tissue infection between October 1, 2015 and September 30, 2016. Inclusion and exclusion criteria were approved by ANW Antimicrobial Stewardship Committee and used to retrospectively identify potential candidates for oritavancin or dalbavancin. Retrospective cost-analysis was performed to assess potential cost savings with the use of dalbavancin or oritavancin instead of the traditional antibiotic therapy that was used. Financial impact was assessed taking into consideration potential cost savings and additional expenses with the use of dalbavancin or oritavancin. Data are presented as mean ± standard deviation. Statistical comparison between actual and predicted length of hospital stay was performed using paired t-test. P < 0.05 was considered statistically significant.
Results. In total, 294 admissions were identified. Eight patients met the selection criteria with the majority being intravenous drug users. Actual length of stay of candidates for dalbavancin or oritavancin was 4.3 ± 2.8 days. Predicted length of hospital stay if dalbavancin or oritavancin were used was 3.0 ± 1.9 days (P = 0.03 vs. actual length of stay). The use of dalbavancin or oritavancin may have prevented four readmissions, two peripherally inserted central catheter insertions, and the use of daptomycin in one patient. Despite the potential cost savings, the use of dalbavancin or oritavancin would result in an additional cost to ANW by an estimate of $937 to $20,107 a year.
Conclusion. Dalbavancin or oritavancin may have been used in a small proportion of admissions (3%) with skin and soft-tissue infection as primary diagnosis. The high cost of dalbavancin and oritavancin offset any potential cost savings resulting in additional costs to ANW estimated to be up to $20,000 a year.
Disclosures. All authors: No reported disclosures. There are few contemporary data on the risk factors and evolving microbiologic trends including drug-resistant organisms implicated in these life-threatening infections.
Emergence of
Methods. A retrospective study of Fournier's gangrene from 2006 to 2015 at a large academic hospital was conducted. Cases were identified using ICD codes V13.89; Z87.438) , and a review of medical and pathology records was performed to confirm each case. Data collected included socio-demographics, medical conditions, bacterial pathogens and their resistance patterns, treatments, and outcome. Descriptive and univariate statistics were performed.
Results. In total, 59 cases were evaluated with an incidence of 31.8 cases per 100,000 admissions over the study period. Mean age was 56 years (range 18-91), 71% were male, and 45% white. Diabetes was noted among 26 (44%) with a mean A1c of 9.6%. Other risk factors included: overweight/obesity (61%), immunocompromised state (34%), and substance use (32%). A causative organism was identified in all but two cases; 12 patients (21%) had an MDRO with MRSA being the most common pathogen (n = 8, 14% of all cases), followed by ESBL E. coli (n = 3) and MDRO Acinetobacter (n = 1). MRSA was the sole pathogen in five (63%) of the eight cases involving this organism. Among those with an aerobic Gram-negative rod (GNR) isolated, 31% were fluoroquinolone-resistant. An MDRO infection was significantly associated with an immunocompromised state (OR 5.5, P = 0.01) and chronic wounds (OR 7.0, P = 0.02). Overall, 30% of all cases had an adverse outcome (15% died and an additional 15% had loss of an organ). Those with MDRO were more likely to experience an adverse outcome (42% vs. 28%), although this was not statistically significant (P = 0.48); of note most (83%) MDRO cases were treated with an initial antibiotic with efficacy against the MDRO.
Conclusion. This report suggests a much higher incidence of Fournier's gangrene than previously described and highlights the emergence of MDROs as an important cause of these infections including MRSA and drug-resistant GNRs. Antibiotics should be chosen with broad-spectrum, anti-MDRO activity given the high morbidity and mortality associated with these infections.
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